MC
EPZM

Muhlenkamp & Co’s Epizyme, Inc EPZM Stock Holding History

Muhlenkamp & Co’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50,000
Closed -$801K – 62
2015
Q4 		$801K Sell
50,000
-2,370
-5% -$35.1K 0.24% 34
2015
Q3 		$673K Buy
52,370
+510
+1% +$10.3K 0.2% 37
2015
Q2 		$1.25M Hold
51,860
– – 0.27% 44
2015
Q1 		$974K Buy
+51,860
New +$1.07M 0.21% 44

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Muhlenkamp & Co's EPZM Position: Q1 2016 in Review

Muhlenkamp & Co sold out of Epizyme, Inc (EPZM) in Q1 2016, closing a stake of 50,000 shares — an estimated $801K sold.

Muhlenkamp & Co first reported a position in EPZM in Q1 2015 and held it in 4 quarters. The position peaked at $1.25M in Q2 2015. 91 funds tracked by Wall St. Rank hold EPZM as of Q1 2016.

  • Muhlenkamp & Co reported no remaining Epizyme, Inc position as of Q1 2016 after selling out during the quarter.
  • Muhlenkamp & Co sold 50,000 Epizyme, Inc shares in Q1 2016, an estimated $801K.
  • Muhlenkamp & Co first reported a position in Epizyme, Inc in Q1 2015 and held it in 4 quarters.
  • Muhlenkamp & Co's Epizyme, Inc position peaked at $1.25M in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2016.

Based on Muhlenkamp & Co's 13F filing for Q1 2016, filed 12 May 2016.